サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1594218

欧州の非侵襲的出生前検査（NIPT）市場：方法別、プラットフォーム別、エンドユーザー別、用途別、国別 - 分析と予測（2023年～2033年）

Europe Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Platform, End User, Application, and Country - Analysis and Forecast, 2023-2033

出版日
発行
BIS Research
ページ情報
英文 78 Pages
納期
1～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
欧州の非侵襲的出生前検査（NIPT）市場：方法別、プラットフォーム別、エンドユーザー別、用途別、国別 - 分析と予測（2023年～2033年）
出版日: 2024年11月21日
発行: BIS Research
ページ情報: 英文 78 Pages
納期: 1～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の非侵襲的出生前検査（NIPT）の市場規模は、2023年に8億5,920万米ドルとなりました。

同市場は、予測期間の2023年～2033年にかけ14.16%のCAGRで拡大し、2033年には32億3,060万米ドルに達すると予測されています。欧州のNIPT市場は主に、有利なガイドラインの導入、償還政策へのスクリーニング手順の組み入れ、技術の継続的な進歩、地域全体での商機拡大、非侵襲的検査法への嗜好の高まりによって牽引されています。

主要市場統計
予測期間 2023年～2033年
2023年の評価 8億5,920万米ドル
2033年予測 32億3,060万米ドル
CAGR 14.16%

欧州における非侵襲的出生前検査（NIPT）市場は、ゲノム技術の発展と、より安全で正確な出生前スクリーニング技術へのニーズの高まりにより、近年大きく成長しています。NIPTとして知られる画期的な方法は、母親の血流中の無細胞胎児DNAを分析することにより、パタウ症候群、エドワーズ症候群、ダウン症候群などの染色体異常を調べるものです。NIPTは非侵襲的であるため、羊水穿刺のような従来の診断技術に伴う危険性がなく、妊娠中の両親や医療関係者に好まれています。

有利な規制の枠組み、患者や医療専門家の知識の増加、公的・私的両方のヘルスケアシステムへのNIPTの組み込みは、すべて市場の成長に寄与しています。NIPTの人気は、特に出生前医療のインフラが確立している地域では、多くの欧州諸国における償還規制によってさらに加速しています。

市場の主要参入企業は、NIPTサービスの手頃な価格、利用しやすさ、精度を向上させる技術の進歩に注力しています。さらに、妊娠後期の傾向や母親の高齢化により、信頼できる出生前スクリーニング方法の必要性が高まっています。その結果、欧州のNIPT市場は着実に拡大し、地域全体の妊産婦と胎児のヘルスケア成果の向上に貢献し、十分な情報に基づいた意思決定を促進すると予想されます。

当レポートでは、欧州の非侵襲的出生前検査（NIPT）市場について調査し、市場の概要とともに、方法別、プラットフォーム別、エンドユーザー別、用途別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 動向：現在および将来の影響評価
  • サプライチェーンの概要
  • 研究開発レビュー
  • 規制状況
  • 償還シナリオ
  • 市場力学の概要

第2章 地域

  • 促進要因と抑制要因
  • 地域別概要
  • 欧州

第3章 市場-競合ベンチマーキングと企業プロファイル

  • 競合情勢
    • F. Hoffmann-La Roche Ltd
    • CENTOGENE N.V.
    • Yourgene Health
    • Eurofins Scientific SE

第4章 調査手法

図表

List of Figures

  • Figure 1: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022, 2026, and 2033
  • Figure 2: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 4: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022, 2026, and 2033
  • Figure 5: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022, 2026, and 2033
  • Figure 6: Non-Invasive Prenatal Testing Market, Recent Developments, 2023
  • Figure 7: Supply Chain of NIPT Market
  • Figure 8: NIPT Market, Patent Analysis, (by Country), January 2020-December 2023
  • Figure 9: NIPT Market, Patent Analysis, (by Year), January 2020-December 2023
  • Figure 10: Reimbursement Scenario in Major Countries of the Europe NIPT Market
  • Figure 11: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 12: Births with Trisomies per 100,000 Live Births in Europe Region, 2000-2021
  • Figure 13: Age of Mother at Childbirth over the Years
  • Figure 14: Reimbursement Scenario in Major Countries
  • Figure 15: Number of Tests Processed by Natera, Inc., 2018-2020
  • Figure 16: Positives from Data of 75,000 NIPT Tests Showing False Positives
  • Figure 17: Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 18: Europe Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 19: France Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 20: France Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 21: Germany Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 22: Germany Non-Invasive Prenatal Testing Market, $Million, 2023-2033
  • Figure 23: U.K. Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 24: U.K. Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 25: Spain Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 26: Spain Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 27: Italy Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 28: Italy Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 29: Rest-of-Europe Non-Invasive Prenatal Testing Market, Thousand Units, 2023-2033
  • Figure 30: Rest-of-Europe Non-Invasive Prenatal Testing Market, $Million, 2022-2033
  • Figure 31: Share of Strategic Initiatives
  • Figure 32: Data Triangulation
  • Figure 33: Top-Down and Bottom-Up
  • Figure 34: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Non-Invasive Prenatal Testing Market, Opportunities
  • Table 3: Key Companies' Partnerships and Alliances
  • Table 4: NIPT Tests in the NIPT Market and their Corresponding Applications
  • Table 5: Risk of Chromosomal Abnormality w.r.t Maternal Age
  • Table 6: Non-Invasive Prenatal Testing Market (by Region), Thousands Units, 2022-2033
  • Table 7: Non-Invasive Prenatal Testing Market (by Region), $Million, 2022-2033
  • Table 8: Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 9: Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 10: Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 11: Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 12: France Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 13: France Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 14: France Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 15: France Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 16: Germany Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 17: Germany Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 18: Germany Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 19: Germany Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 20: U.K. Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 21: U.K. Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 22: U.K. Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 23: U.K. Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 24: Spain Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 25: Spain Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 26: Spain Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 27: Spain Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 28: Italy Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 29: Italy Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 30: Italy Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 31: Italy Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 32: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Application), $Million, 2022-2033
  • Table 33: Rest-of-Europe Non-Invasive Prenatal Testing Market (by End User), $Million, 2022-2033
  • Table 34: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Platform), $Million, 2022-2033
  • Table 35: Rest-of-Europe Non-Invasive Prenatal Testing Market (by Method), $Million, 2022-2033
  • Table 36: Market Share (2022)
目次
Product Code: BHL2393SS

Introduction to Europe Non-Invasive Prenatal Testing (NIPT) Market

The Europe NIPT market was valued at $859.2 million in 2023 and is expected to reach $3,230.6 million by 2033, registering a CAGR of 14.16% during the forecast period 2023-2033. The European NIPT market is primarily driven by the implementation of favorable guidelines, the inclusion of screening procedures in reimbursement policies, ongoing advancements in technology, expanding commercial opportunities across the region, and the growing preference for non-invasive testing methods.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$859.2 Million
2033 Forecast$3,230.6 Million
CAGR14.16%

The market for non-invasive prenatal testing (NIPT) in Europe has grown significantly in recent years due to the development of genomic technologies and the increased need for prenatal screening techniques that are safer and more accurate. The ground-breaking method known as NIPT looks for chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome by analyzing cell-free fetal DNA in the mother's bloodstream. It is a preferred choice for pregnant parents and medical professionals because of its non-invasive nature, which removes the hazards connected to conventional diagnostic techniques like amniocentesis.

Favorable regulatory frameworks, growing patient and healthcare professional knowledge, and the incorporation of NIPT into both public and private healthcare systems all contribute to the market's growth. Its popularity has been further accelerated by reimbursement regulations in a number of European nations, especially in areas with established prenatal care infrastructure.

The market's major players are concentrating on technology advancements to improve the NIPT services' affordability, accessibility, and accuracy. Furthermore, the necessity for trustworthy prenatal screening methods has increased due to the tendency of late pregnancies and the aging of mothers. Consequently, the NIPT market in Europe is expected to increase steadily, contributing to better maternal and fetal healthcare outcomes throughout the area and facilitating informed decision-making.

Market Segmentation:

Segmentation 1: by Application

  • Trisomy Detection
  • Microdeletion Detection
  • Sex Chromosome Aneuploidy Detection
  • Others

Segmentation 2: by End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

Segmentation 3: by Platform

  • NGS
  • PCR
  • Others

Segmentation 4: by Method

  • cfDNA
  • FCMB

Segmentation 5: by Country

  • France
  • Germany
  • Italy
  • Spain
  • U.K.
  • Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Europe NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • F. Hoffmann-La Roche Ltd
  • CENTOGENE N.V.
  • Yourgene Health
  • Eurofins Scientific SE

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
    • 1.1.2 Expanding Applications in NIPT Products
  • 1.2 Supply Chain Overview
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Scenario in the U.K.
    • 1.4.2 Regulatory Scenario in Germany
    • 1.4.3 Regulatory Scenario in France
    • 1.4.4 Regulatory Scenario in Spain
    • 1.4.5 Regulatory Scenario in Italy
    • 1.4.6 Regulatory Scenario in the Netherlands
  • 1.5 Reimbursement Scenario
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 High Incidence of Genetic Disorders
      • 1.6.1.2 Rising Maternal Age
      • 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
      • 1.6.1.4 Increased Emphasis on Early Detection and Prevention
    • 1.6.2 Market Restraints
      • 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
      • 1.6.2.2 Lack of Awareness Regarding NIPT
      • 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)

2 Regions

  • 2.1 Drivers and Restraints
  • 2.2 Regional Summary
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 France
    • 2.3.7 Germany
    • 2.3.8 U.K.
    • 2.3.9 Spain
    • 2.3.10 Italy
    • 2.3.11 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 F. Hoffmann-La Roche Ltd
      • 3.1.1.1 Overview
      • 3.1.1.2 Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
    • 3.1.2 CENTOGENE N.V.
      • 3.1.2.1 Overview
      • 3.1.2.2 Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View
    • 3.1.3 Yourgene Health
      • 3.1.3.1 Overview
      • 3.1.3.2 Product Portfolio
      • 3.1.3.3 Top Competitors
      • 3.1.3.4 Target Customers
      • 3.1.3.5 Key Personnel
      • 3.1.3.6 Analyst View
    • 3.1.4 Eurofins Scientific SE
      • 3.1.4.1 Overview
      • 3.1.4.2 Product Portfolio
      • 3.1.4.3 Top Competitors
      • 3.1.4.4 Target Customers
      • 3.1.4.5 Key Personnel
      • 3.1.4.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast